Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy
This is a pilot phase II study of locally advanced or metastatic nasopharyngeal carcinoma (NPC) with the single drug Alimta. The objective of this study is to assess efficacy and safety profiles of Alimta as 2nd line treatment for patients with advanced NPC.
Nasopharyngeal Neoplasms
DRUG: Pemetrexed (Alimta)
response rate, Jan 2010
progression-free survival, Jan 2010|overall survival, Jan 2010|safety profile of pemetrexed (Alimta) treatment, Jan 2010|pharmacokinetic analysis of half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution, Jan 2010|evaluate the relationship between the expression of alpha folate receptor protein, TS and clinical response, Jan 2010
This is a pilot phase II study of locally advanced or metastatic nasopharyngeal carcinoma (NPC) with the single drug Alimta. The objective of this study is to assess efficacy and safety profiles of Alimta as 2nd line treatment for patients with advanced NPC.